Home » Newsletters » BioWorld Science

BioWorld Science

May 1, 1998

View Archived Issues

ANDA filed for IS-5-MN

Company Profile: Metabasis Therapeutics

AxyS Pharmaceuticals' APC-366 shows good antiasthmatic activity in phase IIa trial

Cypress Bioscience: Q1 1998 highlights

New somatostatin analogues with improved stability and distribution characteristics

European patents issued to Lilly for new benzothiophene compounds

Potent calpain inhibitors disclosed by Mitsubishi Chem.

Taisho scientists isolate cell adhesion inhibitors for arthritis, inflammation and asthma

Lymphocyte-stimulating factor and methods of treating or preventing African sleeping sickness

Update on Repligen's angiogenesis inhibitors

Corvas/Schering-Plough HCV protease collaboration extended

Variagenics licenses diagnostic, therapeutic uses of gene discovered at Mayo Foundation

Feasibility of edible vaccine established in humans

Targeted cytotoxic therapy cures breast cancer in mice at nontoxic doses

Genetronics begins phase II trial of electroporation therapy in U.S.

PowderJect reports positive clinical data for erectile dysfunction product

Improved gastrointestinal delivery of heparin with SNAC

YJA-20379, an H+/K+-ATPase inhibitor that inhibits H. pylori

Cheung Laboratories announces name change

ITF-1779: a novel TNF-alpha inhibitor for sepsis and other inflammatory disorders

rhVEGF promotes angiogenesis in underperfused myocardium

Beneficial effects of tolcapone on sleep disturbances in parkinsonian patients

Lamotrigine evaluated for the treatment of childhood autism

LY-300164 suppresses kindling-induced seizures in mice

First clinical results reported for NPS-1506

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...